Dexamethasone acetate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1973
- First approval year
- 1973
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Dexamethasone acetate
- Molecular weight
- 434.5
- Structure (SMILES)
- CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
- decadron la
- Decadron-la
- dexamethasone acetate
- Dexamethasone acetate
- neofordex
- Neofordex
- BETAMETHASONE ACETATE IMPURITY B [EP IMPURITY]
- betamethasone acetate impurity b ep impurity
- decadronal
- DECADRONAL
- dectancyl
- Dectancyl
- dexamethasone 21 acetate
- dexamethasone 21 acetate mi
- Dexamethasone 21-acetate
- DEXAMETHASONE 21-ACETATE [MI]
- dexamethasone acetate
- Dexamethasone acetate
- DEXAMETHASONE ACETATE [EP MONOGRAPH]
- DEXAMETHASONE ACETATE [USP MONOGRAPH]
- DEXAMETHASONE ACETATE [USP-RS]
- Dexamethasone acetate [WHO-DD]
- DEXAMETHASONE ACETATE [WHO-IP]
- dexamethasone acetate anhydrous
- Dexamethasone acetate anhydrous
- dexamethasone acetate ep monograph
- dexamethasone acetate monohydrate
- Dexamethasone acetate monohydrate
- dexamethasone acetate usp monograph
- dexamethasone acetate usp rs
- dexamethasone acetate who dd
And 15 more, listed on the interactive page.
- CAS registry numbers
- 1177-87-3
- ChEMBL ID
- CHEMBL1530428
- InChIKey
- AKUJBENLRBOFTD-RPRRAYFGSA-N
- PubChem compound IDs
- 236702
- FDA ingredient codes (UNII)
- K7V8P532WP
- 22690
- 2378841
- Applicant
- MERCK
- Approval date
- 6 Sept 1973
- Application number
- NDA016675
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
- United States (FDA)
- Approved
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Multiple Myeloma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Pancreatitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000652
- Subject identifier
- D010195
- Condition
- Tooth Diseases
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:1001216
- Subject identifier
- D014076
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000652
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001216
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 2
- Event
- anaphylactic shock
- Reports
- 7
- Reporting signal score
- 9.52004
- Event
- aphthous ulcer
- Reports
- 6
- Reporting signal score
- 15.8134
- Event
- arterial thrombosis limb
- Reports
- 3
- Reporting signal score
- 12.8005
- Event
- cheilitis
- Reports
- 6
- Reporting signal score
- 17.1869
- Event
- conjunctival irritation
- Reports
- 6
- Reporting signal score
- 36.3485
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 17
- Reporting signal score
- 32.9663
- Event
- eosinophilia
- Reports
- 8
- Reporting signal score
- 13.0952
- Event
- febrile bone marrow aplasia
- Reports
- 428
- Reporting signal score
- 887.334
- Event
- febrile neutropenia
- Reports
- 1,923
- Reporting signal score
- 2,236.59
- Event
- genital erythema
- Reports
- 6
- Reporting signal score
- 33.0206
- Event
- hepatic cytolysis
- Reports
- 6
- Reporting signal score
- 17.8414
- Event
- hypertriglyceridaemia
- Reports
- 5
- Reporting signal score
- 10.6017
- Event
- hyphaema
- Reports
- 3
- Reporting signal score
- 12.1652
- Event
- interstitial lung disease
- Reports
- 11
- Reporting signal score
- 12.8394
- Event
- meningioma
- Reports
- 4
- Reporting signal score
- 10.8036
- Event
- necrotising ulcerative gingivostomatitis
- Reports
- 5
- Reporting signal score
- 32.1315
- Event
- neuropathy peripheral
- Reports
- 1,605
- Reporting signal score
- 1,287.82
- Event
- neutropenia
- Reports
- 2,480
- Reporting signal score
- 1,836.89
- Event
- neutrophil count decreased
- Reports
- 10
- Reporting signal score
- 12.2349
- Event
- pigmentary glaucoma
- Reports
- 2
- Reporting signal score
- 13.682
- Event
- plasma cell myeloma
- Reports
- 1,660
- Reporting signal score
- 2,960.49
- Event
- platelet count decreased
- Reports
- 14
- Reporting signal score
- 10.8644
- Event
- polyneuropathy
- Reports
- 8
- Reporting signal score
- 16.7452
- Event
- pyrexia
- Reports
- 29
- Reporting signal score
- 14.9648
- Event
- rash erythematous
- Reports
- 12
- Reporting signal score
- 19.7153
And 5 more, listed on the interactive page.
- NCT00635154
- NCT01916252
- NCT05052970
- NCT00651261
- NCT01247961
- NCT01421173
- NCT01878708
- NCT02837614
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 100.9
- Calculated partition coefficient (ALogP)
- 2.47
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 31
- Molecular formula
- C24H31FO6
- Monoisotopic mass
- 434.21046687
- Natural product
- No
- Recorded assays
- 2,086
- Active assays
- 63
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
Related records
Trials (83)
- A Long-Term Safety Study of OZURDEX® in Clinical Practice
- A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
- A Prospective Controlled Treatment Trial for Post-Traumatic Headaches
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
- A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
- A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
- An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
- Analgesic Efficacy of Dexamethasone in Different Routes of Administration in Transverse Abdominis Plane Block
- Anosmia and / or Ageusia and Early Corticosteroid Use
- Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
- Comparing DCP and DAP for Pemphigus Vulgaris
- Comparing Single Dose and Multiple Dose of Dexamethasone Post TKA
- Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction
- Comparison of Acetaminophen With Aminophylline and Aminophylline With Dexamethasone for Prophylaxis of PDPH in Patients With History of PDPH.
- Comparison of Analgesic Consumption Between Perioperative ıv Dexamethasone and Added to Femoral Block
- Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup
Approved for (1)
In development for (4)
Targets (1)
- NR3C1 Glucocorticoid receptor agonist